Geron Corporation Initiates Clinical Trial of GRN163L in Combination with Paclitaxel and Bevacizumab in Patients with Breast Cancer

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer.